[{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"4d2d76d4-435a-440f-8e0e-92bf66cb6dca","acronym":"NRG-GY019","url":"https://clinicaltrials.gov/study/NCT04095364","created_at":"2021-01-18T20:02:20.500Z","updated_at":"2024-07-02T16:35:06.502Z","phase":"Phase 3","brief_title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04095364 - NRG-GY019","lead_sponsor":"NRG Oncology","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-02"},{"id":"44ebbc97-9bac-4aa0-aaf1-361a99cfa91f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02659241","created_at":"2021-01-18T12:57:18.393Z","updated_at":"2024-07-02T16:35:09.936Z","phase":"Phase 1","brief_title":"Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02659241","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":" | ","alterations":" TP53 mutation • TP53 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 02/04/2016","start_date":" 02/04/2016","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-12"},{"id":"b5a8ef91-57f8-40d4-86d6-390343c25e8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03303846","created_at":"2021-01-18T16:19:09.823Z","updated_at":"2024-07-02T16:35:11.087Z","phase":"","brief_title":"Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients","source_id_and_acronym":"NCT03303846","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" TP53 mutation • TP53 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 344","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 04/25/2026","primary_completion_date":" 04/25/2026","study_txt":" Completion: 04/25/2026","study_completion_date":" 04/25/2026","last_update_posted":"2024-04-08"},{"id":"20ab3da1-4b1b-4645-a925-205f881a9a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432963","created_at":"2021-01-17T18:04:39.866Z","updated_at":"2024-07-02T16:35:14.012Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","source_id_and_acronym":"NCT02432963","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MSI","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/14/2016","start_date":" 06/14/2016","primary_txt":" Primary completion: 12/04/2017","primary_completion_date":" 12/04/2017","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"277f8fcd-b41c-46ce-afa0-e0dbc651dba0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06045572","created_at":"2023-09-21T15:10:54.497Z","updated_at":"2024-07-02T16:35:18.031Z","phase":"","brief_title":"Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer","source_id_and_acronym":"NCT06045572","lead_sponsor":"Galzu Institute of Research, Teaching, Science and Applied Technology","biomarkers":" TP53 • BRCA1 • PTEN • STK11 • S100P","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • TP53 expression","tags":["TP53 • BRCA1 • PTEN • STK11 • S100P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • TP53 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-02-22"},{"id":"0c45dd0e-f439-463b-8d1f-a9be494b9943","acronym":"","url":"https://clinicaltrials.gov/study/NCT02808650","created_at":"2021-01-18T13:46:35.607Z","updated_at":"2024-07-02T16:35:25.681Z","phase":"Phase 1","brief_title":"Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02808650","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":" | ","alterations":" TP53 mutation • TP53 deletion • TP53 expression","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2017","start_date":" 02/27/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2023-12-20"},{"id":"f819fdca-d47b-44d9-bff9-cba461ae961d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214626","created_at":"2021-01-18T20:31:21.284Z","updated_at":"2024-07-02T16:35:27.097Z","phase":"Phase 2","brief_title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04214626","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression • TP53 expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 11/29/2023","primary_completion_date":" 11/29/2023","study_txt":" Completion: 01/02/2025","study_completion_date":" 01/02/2025","last_update_posted":"2023-12-05"},{"id":"3833f599-a08b-4372-871c-e2dd1bb85b90","acronym":"","url":"https://clinicaltrials.gov/study/NCT06148129","created_at":"2023-11-28T19:16:49.858Z","updated_at":"2024-07-02T16:35:27.926Z","phase":"","brief_title":"Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients","source_id_and_acronym":"NCT06148129","lead_sponsor":"Zagazig University","biomarkers":" TP53 • L1CAM","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • L1CAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 01/12/2019","start_date":" 01/12/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2023-11-28"},{"id":"c24bf18c-c610-4773-9dc4-8e8a58052ad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06080841","created_at":"2023-10-12T21:14:04.161Z","updated_at":"2024-07-02T16:35:33.676Z","phase":"","brief_title":"Curcumin Supplementation in Cervical Cancer","source_id_and_acronym":"NCT06080841","lead_sponsor":"National Institute of Cancerología","biomarkers":" TP53 • ANXA5","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-10-12"},{"id":"0804d990-b4fa-44fe-9d8a-738f29afd92f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015269","created_at":"2023-08-29T16:10:06.647Z","updated_at":"2024-07-02T16:35:38.725Z","phase":"Phase 1","brief_title":"Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery","source_id_and_acronym":"NCT06015269","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" TP53","pipe":" | ","alterations":" TP53 expression • BIRC5 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • BIRC5 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-08-29"},{"id":"f8ed6327-22c2-4627-8859-fcf06853c05a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005870","created_at":"2023-08-23T16:10:47.442Z","updated_at":"2024-07-02T16:35:39.161Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression","source_id_and_acronym":"NCT06005870","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" TP53","pipe":" | ","alterations":" TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • vincristine • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/26/2022","start_date":" 11/26/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-08-23"},{"id":"4415345d-a697-4291-8d70-7d0798eb8ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945407","created_at":"2023-07-14T18:08:53.504Z","updated_at":"2024-07-02T16:35:42.902Z","phase":"","brief_title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","source_id_and_acronym":"NCT05945407","lead_sponsor":"Peking University People's Hospital","biomarkers":" TP53 • PTEN • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • PTEN • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-07-14"},{"id":"1012db51-d55b-4d8c-b8ab-1c5ef93eacbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01500733","created_at":"2021-01-17T17:35:10.604Z","updated_at":"2024-07-02T16:35:50.070Z","phase":"Phase 2","brief_title":"PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01500733","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TP53 • CD20 • CD5 • FCER2","pipe":" | ","alterations":" TP53 mutation • CD20 expression • CD19 expression • TP53 expression","tags":["TP53 • CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 expression • CD19 expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 01/05/2012","start_date":" 01/05/2012","primary_txt":" Primary completion: 06/20/2014","primary_completion_date":" 06/20/2014","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-04-19"},{"id":"79ff0d7f-8e12-46e7-a59f-373c976c10bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638542","created_at":"2022-12-06T15:57:57.071Z","updated_at":"2024-07-02T16:35:50.646Z","phase":"","brief_title":"Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp","source_id_and_acronym":"NCT05638542","lead_sponsor":"Seoul National University Bundang Hospital","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • TP53 • MSI • MLH1 • MSH6 • MSH2 • PMS2 • RUNX3 • IL1B • NLRP3 • NEUROG1 • CASP1","pipe":" | ","alterations":" PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR expression • PMS2 mutation • TP53 expression • PD-L1 mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • TP53 • MSI • MLH1 • MSH6 • MSH2 • PMS2 • RUNX3 • IL1B • NLRP3 • NEUROG1 • CASP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR expression • PMS2 mutation • TP53 expression • PD-L1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 582","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 01/30/2021","primary_completion_date":" 01/30/2021","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-13"},{"id":"42ddb378-1446-4084-a290-35601a846939","acronym":"","url":"https://clinicaltrials.gov/study/NCT05703815","created_at":"2023-01-30T18:59:49.220Z","updated_at":"2024-07-02T16:35:56.697Z","phase":"","brief_title":"EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast","source_id_and_acronym":"NCT05703815","lead_sponsor":"Sohag University","biomarkers":" TP53 • EPCAM","pipe":" | ","alterations":" TP53 expression • EPCAM expression","tags":["TP53 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • EPCAM expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2023-01-31"},{"id":"42fec90d-1616-4bcb-ba10-1468cd201d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568212","created_at":"2022-10-05T12:56:03.628Z","updated_at":"2024-07-02T16:36:02.981Z","phase":"Phase 2","brief_title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","source_id_and_acronym":"NCT05568212","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TP53 expression","tags":["TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-10-05"},{"id":"255ffbc3-1ae8-4087-ae88-e4e032dedb1a","acronym":"IMPEC","url":"https://clinicaltrials.gov/study/NCT03346954","created_at":"2021-01-18T16:31:45.427Z","updated_at":"2024-07-02T16:36:37.966Z","phase":"","brief_title":"Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease","source_id_and_acronym":"NCT03346954 - IMPEC","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" TP53","pipe":" | ","alterations":" TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/11/2017","start_date":" 12/11/2017","primary_txt":" Primary completion: 06/11/2019","primary_completion_date":" 06/11/2019","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2020-12-01"},{"id":"9ba1fa58-3a34-4e19-a5e3-b32641970e8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02123381","created_at":"2021-01-18T09:50:16.450Z","updated_at":"2024-07-02T16:36:48.334Z","phase":"Phase 2","brief_title":"Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT02123381","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" TP53 • BIRC5","pipe":" | ","alterations":" TP53 expression • BIRC5 expression","tags":["TP53 • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-03-17"},{"id":"91f25517-3648-4010-96ee-c139f5875d49","acronym":"CABA-BONE","url":"https://clinicaltrials.gov/study/NCT02512458","created_at":"2021-01-18T12:08:14.634Z","updated_at":"2024-07-02T16:36:50.251Z","phase":"Phase 2","brief_title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","source_id_and_acronym":"NCT02512458 - CABA-BONE","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" TP53 • AR • CYP17A1 • NKX3-1 • UBE2C","pipe":" | ","alterations":" AR expression • TP53 expression","tags":["TP53 • AR • CYP17A1 • NKX3-1 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/27/2019","study_completion_date":" 12/27/2019","last_update_posted":"2020-02-10"},{"id":"f5bb9bb3-4a13-427c-a0c0-821104f69000","acronym":"","url":"https://clinicaltrials.gov/study/NCT02747355","created_at":"2021-01-18T13:27:36.540Z","updated_at":"2024-07-02T16:37:03.677Z","phase":"","brief_title":"Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors","source_id_and_acronym":"NCT02747355","lead_sponsor":"Bnai Zion Medical Center","biomarkers":" TP53 • NRP1 • MCM2 • MCM3 • SEMA3A","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • NRP1 • MCM2 • MCM3 • SEMA3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 70","initiation":"Initiation: 08/18/2016","start_date":" 08/18/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-18"},{"id":"2a3a4958-56e6-4116-af7e-25e6b74f71f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00392834","created_at":"2021-01-18T01:22:18.986Z","updated_at":"2024-07-02T16:37:10.246Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","source_id_and_acronym":"NCT00392834","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" TP53 • CFLAR","pipe":" | ","alterations":" TP53 mutation • TP53 expression • CFLAR expression","tags":["TP53 • CFLAR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • CFLAR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2018-06-06"},{"id":"b4eb2ce4-ce5e-4719-a980-3012b29e1492","acronym":"","url":"https://clinicaltrials.gov/study/NCT02275039","created_at":"2021-01-18T10:42:22.245Z","updated_at":"2024-07-02T16:37:11.146Z","phase":"Phase 1","brief_title":"p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer","source_id_and_acronym":"NCT02275039","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • p53MVA"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 04/23/2018","primary_completion_date":" 04/23/2018","study_txt":" Completion: 04/23/2018","study_completion_date":" 04/23/2018","last_update_posted":"2018-04-30"},{"id":"f0387d12-fa4e-40e1-addf-226e0d4ad5ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00900328","created_at":"2021-01-18T03:28:03.237Z","updated_at":"2024-07-02T16:37:19.075Z","phase":"","brief_title":"Study of Tumor Samples From Patients With Lung Cancer","source_id_and_acronym":"NCT00900328","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" EGFR • KRAS • ALK • TP53 • MET • CBL","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression","tags":["EGFR • KRAS • ALK • TP53 • MET • CBL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression"],"overall_status":"Completed","enrollment":" Enrollment 280","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2017-08-08"}]